Filing Details

Accession Number:
0000890465-14-000008
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-01-09 16:53:47
Reporting Period:
2014-01-07
Filing Date:
2014-01-09
Accepted Time:
2014-01-09 16:53:47
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
890465 Nps Pharmaceuticals Inc NPSP Biological Products, (No Disgnostic Substances) (2836) 870439579
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1192128 M Luke Beshar 550 Hills Drive
Bedminster NJ 07921
Evp & Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-01-08 31,588 $3.34 90,768 No 4 M Direct
Common Stock Disposition 2014-01-08 31,588 $35.01 59,180 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options Acquisiton 2014-01-07 8,625 $0.00 8,625 $3.34
Common Stock Stock Options Disposition 2014-01-08 31,588 $0.00 31,588 $3.34
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
106,376 2020-02-19 No 4 A Direct
74,788 2020-02-19 No 4 M Direct
Footnotes
  1. The shares were sold pursuant to a predefined price target in a trading plan qualified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, that was effective December 12, 2013.
  2. The price shown above represents the weighted average price of the shares sold. The range of sales prices was $35.00 and $35.02. The Reporting Person will provide to the Issuer, any security holder of the Issuer, or the SEC Staff, upon request, information regarding the number of shares sold at each price within the range of prices actually paid.
  3. On February 19, 2010, the Reporting Person was granted options to purchase shares of Common Stock under the Issuer's 2005 Omnibus Incentive Plan, which are subject to both performance conditions and time-based vesting. On January 7, 2014, the performance criteria for 8,625 of these options was satisfied when the FDA accepted the BLA for Natpara for the treatment of hypoparathyroidism. As of January 7, 2014, the performance criteria and the time-based criteria for 71,156 of these options has been satisfied. These options will vest and become exercisable based on the following vesting schedule: 25% on each of the first four anniversaries of the date of grant.
  4. On February 19, 2010, the Reporting Person was granted options to purchase shares of Common Stock under the Issuer's 2005 Omnibus Incentive Plan, which are subject to both performance conditions and time-based vesting. As of January 8, 2014, the performance criteria and the time-based criteria for 71,156 of these options has been satisfied. The options become exercisable based on the following vesting schedule: 25% on each of the first four anniversaries of the date of grant.